ArticleAACE endocrinology and diabetes
Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.Advances in therapy · 2026Review
- The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review.Diabetologia · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Cystic fibrosis (CF)-related diabetes (CFRD) is a common extrapulmonary complication of CF, with increasing prevalence. As individuals with CF live longer, obesity rates are increasing, leading to an emerging phenotype called CFRD with metabolic syndrome. The objective of this report is to describe the use of semaglutide in an adult with CFRD, obesity, and clinical insulin resistance. Case Report: A 32-year-old man with CF, pancreatic insufficiency, obesity, and poorly controlled CFRD presented with worsening blood sugar control, increasing insulin requirements, and a strong family history of metabolic syndrome. His body mass index was 38.5 kg/m Discussion: Although insulin is the primary treatment for CFRD, glucagon-like peptide 1 receptor agonists may provide additional benefits in carefully selected patients. Conclusion: This case highlights the potential benefits of glucagon-like peptide 1 receptor agonists in CFRD with metabolic syndrome and emphasizes the need for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.